Recently, Ultragenyx Pharmaceutical (RARE) announced that it had failed to meet the primary endpoint of a phase 3 study. This phase 3 study used a drug known as UX007 treating a rare genetic disorder known as Glucose Transporter Type 1 Deficiency Syndrome or Glut1DS. While the results are disappointing, UX007 is being explored in another indication known as long-chain fatty oxidation disorder. On top of that, Ultragenyx has two approved products and an initial pipeline for gene therapy. I believe that this selloff may offer a good entry point. For that reason,